<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342444</url>
  </required_header>
  <id_info>
    <org_study_id>8080</org_study_id>
    <nct_id>NCT02342444</nct_id>
  </id_info>
  <brief_title>Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)</brief_title>
  <official_title>A Prospective Randomized Trial Comparing Two Standard Doses of Enoxaparin for the Prevention of Thromboembolism in Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many
      times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing
      clots in their legs or lungs. There are two standard doses of enoxaparin that are recommended
      by the drug companies. These two doses have never been directly compared in trauma, general,
      and vascular surgery patients. The purposes of this study are:

        1. to compare the development of blood clots in patients receiving 30mg twice daily of
           enoxaparin compared to patients receiving 40mg once daily of enoxaparin.

        2. to determine if there is higher risk of bleeding complications in patients receiving
           30mg twice daily of enoxaparin compared to patients receiving 40mg once daily.

      Patients enrolled into the study will be randomized to receive enoxaparin, 30mg twice daily
      or enoxaparin, 40mg once daily. Patients will then be monitored for signs and symptoms of
      blood clots. At the time of discharge (or before, if medically indicated), an ultrasound test
      will be performed to look for blood clots in the patient's legs.

      The investigators will compare incidence of blood clots formed between the 2 groups of
      patients to determine if one dose of enoxaparin relates to a lower rate of blood clots in
      critically ill patients. The investigators will also compare the incidence of bleeding
      complications between the 2 groups.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>Daily, up to Day 90</time_frame>
    <description>Daily monitoring per standard of care for the development of thromboembolic events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in bleeding complications</measure>
    <time_frame>Daily, up to Day 90</time_frame>
    <description>Daily monitoring for an increase in bleeding complications due to study drug dose and regime.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Trauma</condition>
  <condition>Surgery</condition>
  <condition>Deep Vein Thrombosis (DVT)</condition>
  <condition>Thromboembolic Events</condition>
  <arm_group>
    <arm_group_label>Enoxaparin Sodium Injection 30 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are randomized to receive 30 mg twice daily of enoxaparin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin Sodium Injection 40 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are randomized to receive 40 mg once daily of enoxaparin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin Sodium Injection 30 mg BID</intervention_name>
    <arm_group_label>Enoxaparin Sodium Injection 30 mg BID</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin Sodium Injection 40 mg QD</intervention_name>
    <arm_group_label>Enoxaparin Sodium Injection 40 mg QD</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted patients requiring prophylactic dosing of enoxaparin (Lovenox)

          -  Admitted to the trauma or surgical service

          -  Age greater than 15 years

        Exclusion Criteria:

          -  Unable to obtain consent from patient or authorized representative

          -  Presence of intracranial hemorrhage

          -  Receiving therapeutic dose of enoxaparin (Lovenox)

          -  Receiving other forms of anticoagulation

          -  Presence of renal failure requiring non-standard dosing regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheri Watson, BS</last_name>
    <phone>503 494-4315</phone>
    <email>watsoch@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha Underwood, MS</last_name>
    <phone>503 494-8481</phone>
    <email>underwos@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheri Watson, BS</last_name>
      <phone>503-494-4315</phone>
      <email>watsoch@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Underwood, MS</last_name>
      <phone>503 494-8481</phone>
      <email>underwos@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mackenzie Cook, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philbert Van, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>January 14, 2015</last_update_submitted>
  <last_update_submitted_qc>January 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Martin Schreiber</investigator_full_name>
    <investigator_title>Professor &amp; Chief of Trauma</investigator_title>
  </responsible_party>
  <keyword>Trauma</keyword>
  <keyword>Surgery</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>DVTs</keyword>
  <keyword>Thromboembolic events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

